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Steroid 21-hydroxylase deficiency is caused by a defect in the CYP21A2 gene. CYP21A2, the adjacent
complement C4 gene and parts of the flanking genes RP1 and TNXB constitute a tandemly duplicated
arrangement in the central (class III) region of the major histocompatibility complex. The typical number of
repeats of the CYP21/C4 region is two, with one repeat carrying CYP21A2 and the other carrying the highly
homologous pseudogene CYP21A1P. By comparison with this standard, three categories of CYP21A2
defects have traditionally been distinguished: CYP21A2 deletions, large-scale gene conversions of CYP21A2
into a structure similar to CYP21A1P, and smaller mutations in CYP21A2 (also derived from CYP21A1P, by
means of small-scale gene conversions). The genetic mechanisms suggested by these designations have
originally been inferred from the layout of the haplotypes involved and were later confirmed by observation of
deletions and small mutations, but not large-scale conversions, as de novo events. Apparent large-scale
conversions account for the defect in 9 out of 77 chromosomes in our patient group. We here demonstrate
that 4 out of these 9 ‘conversions’ extend into the flanking TNXB gene, which encodes tenascin-X. This
implies that 1 in every 10 steroid 21-hydroxylase deficiency patients is a carrier of tenascin-X deficiency,
which is associated with a recessive form of the Ehlers–Danlos syndrome. Currently available data on the
structure of ‘deletion’ and ‘large-scale conversion’ chromosomes strongly suggests that both are the result
of the same mechanism, namely unequal meiotic crossover. Since it is unlikely that the term ‘large-scale gene
conversion’ describes a mechanism that actually occurs between the CYP21A2 and CYP21A1P genes, we
propose the discontinuation of that terminology.
INTRODUCTION
Steroid 21-hydroxylase deficiency is the foremost cause of
congenital adrenal hyperplasia (CAH), an inborn error of
metabolism with an incidence ranging between 1 : 10 000 and
1 : 15 000 in most populations (1–5). CAH due to
21-hydroxylase deficiency is characterized by an impaired
adrenocortical synthesis of cortisol and aldosterone. Lack of
aldosterone often results in severe salt loss in untreated
paediatric patients, a potentially life-threatening condition.
Also, the adrenal, which has increased in size due to
continuous adrenocorticotrophic hormone (ACTH) stimulation
induced by lack of cortisol, shunts excess precursor steroids
into the androgen synthesis pathway. The elevated androgen
levels then cause pre- and postnatal virilization.
Steroid 21-hydroxylase deficiency has a wide range of
clinical manifestations that are associated with more or less
severe defects of the CYP21A2 gene. Over 15 years ago, it was
found that CYP21A2 and the highly homologous but deficient
pseudogene CYP21A1P lie in the central region of the human
major histocompatibility complex (MHC) near the two genes
encoding the fourth component of complement (C4A and C4B)
in a tandemly duplicated arrangement (6,7). The C4 genes may
be 20.5 or 14.2 kb in size, depending on the presence or
absence of an endogenous retroviral sequence in the ninth
intron. On the telomeric side, the CYP21/C4 region is flanked
by the RP1 gene (also named G11 or STK19), which encodes a
serine–threonine kinase (8–10). Centromeric to the CYP21/C4
region lies TNXB, which encodes the extracellular matrix
protein tenascin-X (11–13). The stretch of DNA that is
duplicated encompasses part of RP1, all of C4, all of CYP21
and part of TNXB. In this report, we will use the shorthand
notation ‘RCCX module’ (9,14,15), derived from the names of
the above-mentioned genes (RP–C4–CYP21–TNX) for the
duplicated region. The RCCX module may be ‘long’ or ‘short’
depending on the size of the C4 gene. Most chromosomes bear
two modules, with a CYP21A2 gene in the centromeric and
a CYP21A1P gene in the telomeric position (Fig. 1), but
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monomodular and trimodular haplotypes are common in
most populations studied (2,15), including the Dutch (16).
The duplicated sections of TNXB and RP1 are truncated
pseudogenes named TNXA and RP2, respectively.
TaqI and BglII restriction analyses of genomic DNA have
become tried-and-proven methods to establish the overall
genetic arrangement of the CYP21/C4 region (7,17–22). TaqI
polymorphisms are especially useful because they provide
information about several genes: (i) because of a polymorphism
in the 50 flank, CYP21A2 is characterized by a 3.7 kb TaqI
fragment and CYP21A1P by a 3.2 kb fragment (6,7);
(ii) because of a 120 bp deletion in TNXA that does not occur
in TNXB (11–14), TNXB is characterized by a 2.5 kb TaqI
fragment and TNXA by a 2.4 kb fragment (7,21); (iii) the size
and the position (but not the C4A or C4B specificity) of the C4
genes can be deduced: a telomeric ‘long’ C4 gene is
characterized by a 7.0 kb TaqI fragment, a telomeric ‘short’
C4 gene by a 6.4 kb fragment, a non-telomeric ‘long’ C4 gene
by a 6.0 kb TaqI fragment and a non-telomeric ‘short’ C4 gene
by a 5.4 kb fragment (in this context, the term ‘telomeric’ refers
to the C4 gene adjacent to RP1, and ‘non-telomeric’ to C4
genes adjacent to RP2) (15,18,22). BglII restriction patterns
show the number of modules: there is always one 11 kb
fragment representing the centromeric module, and a 12 kb
fragment for each of the other modules. These fragments and
probing strategies used to detect them have been discussed in
detail elsewhere (2,18,20–22).
Studies of TaqI and BglII restriction fragment ratios of
21-hydroxylase deficiency alleles early on led to their
classification into three main categories of defects:
(1) chromosomes with a CYP21A1P-like gene and no
CYP21A2 gene (‘CYP21A2 deletions’);
(2) chromosomes with two CYP21A1P-like genes and no
CYP21A2 gene (‘large-scale gene conversions’);
(3) chromosomes with at least one (defective) CYP21A2
gene; here, further analysis demonstrated that most (but not all)
defective CYP21A2 genes carried one or more of a limited set
of mutations typically found in CYP21A1P, and these defects
were therefore designated ‘small-scale gene conversions’.
Although the names of these categories suggest that each has
been generated by a specific genetic mechanism, this
classification was primarily based on the difference between
each category and the typical arrangement shown in Figure 1
(with one CYP21A2 and one CYP21A1P gene). It was soon
recognized that the first two categories (‘deletions’ and ‘large-
scale conversions’) typically carry a hybrid gene with the
50 portion of CYP21A1P joined onto the 30 portion of
CYP21A2 (20,23–26). Since the 50 portion contains the extra
TaqI site (6,7,27), the hybrid is recognized as a CYP21A1P-like
gene in restriction analysis of genomic DNA. However, since
the neighbouring TNXB gene remains unaffected in such
hybrids, its characteristic 2.5 kb TaqI fragment is retained.
Consequently, the ratio between the 12 and 11 kb BglII
fragments is the same as between the 2.4 and 2.5 kb TaqI
fragments in these haplotypes (2,21).
Unequal meiotic crossover is believed to be the mechanism
causing CYP21A2 deletions, a notion firmly supported by studies
of deletion haplotypes (7,20,23,28–30) and de novo events (31;
P.F.J. Koppens, H.J.M. Smeets, I.J. de Wijs and H.J. Degenhart,
manuscript in preparation). The location of the recombination
breakpoint determines the size of the pseudogene-like portion,
and hence the genetic defects carried by these deletion
chromosomes. While in rare cases, enough of CYP21A2 has
been retained to produce a partially active 21-hydroxylase
enzyme (32), nearly all of the hybrid genes studied so far
include at least an 8 bp deletion in the third exon, leading to
premature termination of translation (24–26,29,30). Recently,
breakpoint locations beyond the 30 end of CYP21A2 have been
Figure 1. Overview of the C4/CYP21 area, showing two RCCX modules as found on most chromosomes. TNXB is the full-size 68 kb gene for tenascin-X, TNXA
(shown as a hatched box; also known as XA) is a truncated pseudogene of 5.7 kb that lacks most of the coding sequence of TNXB and has a deletion of 120 bp
(indicated by the small triangle) spanning an exon–intron boundary (11–14). CYP21A2 (also known as CYP21B) is the active steroid 21-hydroxylase gene;
CYP21A1P (shown in black; also known as CYP21A) is a full-size pseudogene containing several deleterious mutations throughout its sequence, including three
in-phase stop codons (27). The C4 genes express variants of the fourth component of complement with different affinities, known as C4A and C4B. The arrange-
ment with C4A in the telomeric and C4B in the centromeric module is common, but the specificity of the C4 genes cannot be determined by means of the res-
triction sites shown, and many alternative arrangements have been described in the literature. About three-quarters of all RCCX modules are ‘long’ (33 kb in size);
the others are ‘short’ (27 kb). The difference depends on the presence or absence of an endogenous retroviral sequence in one of the introns of the C4 gene.
The arrows show the orientation of transcription; there is an overlap between the 30 sections of the oppositely transcribed genes TNXB and CYP21A2, and of TNXA
and CYP21A1P, respectively. Bottom: characteristic TaqI and BglII restriction fragments. Top: scale in kb, with the centromeric RCCX duplication boundary at 0.
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found (14,33,34; P.F.J. Koppens, H.J.M. Smeets, I.J. de Wijs,
H.J. Degenhart, manuscript in preparation). Such alleles carry an
additional genetic defect, because a part of the tenascin-X-
producing TNXB gene has been replaced by its TNXA counter-
part, containing a 120 bp deletion on an exon–intron boundary. In
these haplotypes, the TNXB–TNXA hybrid is characterized
by a 2.4 kb rather than a 2.5 kb TaqI fragment, and the above-
mentioned parity with the BglII 12 and 11 kb fragment ratio
does not apply. A homozygous defect of TNXB causes type II
Ehlers–Danlos syndrome, a connective-tissue disease (33,34).
Insight into the mechanisms of gene conversions has not
progressed at the same pace, however. The ‘large-scale gene
conversion’ chromosomes with two CYP21A1P-like genes (that
is, two genes characterized by a 3.2 kb TaqI fragment) indeed
carry a stretch of CYP21A1P-like DNA encompassing several
exons (25,26), although here too an exception where the
‘converted’ region was limited in size and the gene retained
some activity has been demonstrated (35). Most ‘small-scale
gene conversions’, on the other hand, involve a stretch of
CYP21A1P-like DNA that is at most a few hundred base pairs
in size and contains only one recognizable mutation as a marker
of ‘CYP21A1P-ness’.
We here report on the extension of the pseudogene-like region
in bimodular chromosomes with two CYP21A1P-like genes
(termed ‘large-scale gene conversions’ in the above-mentioned
categorization). Out of nine such haplotypes in a population of
steroid 21-hydroxylase deficiency from 39 families studied by us,
five had a CYP21A1P–CYP21A2 transition zone in the CYP21A2
gene, but the other four were pseudogene-like well into the TNXB
gene. This implies that 10% of the patients with classical
21-hydroxylase deficiency in the population that we studied are
also carriers of tenascin-X deficiency. Thus, defectiveness of the
TNXB gene due to the 120 bp deletion normally found in the TNXA
pseudogene appears to be much more common than previously
reported, and also much more common in bimodular ‘conversion’
haplotypes than in monomodular ‘deletion’ haplotypes.
RESULTS
CYP21/C4 haplotyping
We determined CYP21/C4 haplotypes in a population of 39
Dutch families of steroid 21-hydroxylase deficiency patients
Table 1. Family studies of bimodular CYP21/C4/TNX haplotypes without a CYP21A2 gene
Persona CYP21A2 probe C4 probe PflMI digest of TNXB PCR
productb
Haplotype codesc
TaqI 3.7 : 3.2 2.5 : 2.4 BglII 11 : 12 TaqI 7.0 : 6.4 : 6.0 : 5.4 2808 2688 2344
3Fd 2 : 2 2 : 2 2 : 2 2 : 0 : 1 : 1 þ 7 7 A A*
3Md 1 : 3 2 : 2 2 : 2 2 : 0 : 1 : 1 þ 7 7 A D*
3Pd 1 : 3 2 : 2 2 : 2 2 : 0 : 1 : 1 þ 7 7 A* D*
14Me 1 : 3 —f 2 : 2 2 : 0 : 1 : 1 þ 7 þ A1 D2x*
14Pe 0 : 4 1 : 3 2 : 2 2 : 0 : 1 : 1 þ 7 þ D1* D2x*
14Se 1 : 3 —f 2 : 2 2 : 0 : 1 : 1 þ 7 þ A1 D2x*
14Se 1 : 3 2 : 2 2 : 2 2 : 0 : 2 : 0 þ 7 7 D1* A1
15F 1 : 2 2 : 1 2 : 1 1 : 1 : 1 : 0 þ 7 7 B2 D1*
15M 2 : 2 2 : 2 2 : 2 2 : 0 : 1 : 1 þ 7 7 A2 A1*
15P 1 : 3 2 : 2 2 : 2 2 : 0 : 2 : 0 þ 7 7 D1* A1*
15S 2 : 1 2 : 1 2 : 1 1 : 1 : 0 : 1 þ 7 7 B2 A2
16F 1 : 2 2 : 1 2 : 1 2 : 0 : 1 : 0 þ 7 7 A1 E1*
16M 1 : 3 1 : 3 2 : 2 2 : 0 : 1 : 1 þ þ 7 A1 D2x*
16P 0 : 3 1 : 2 2 : 1 2 : 0 : 0 : 1 þ þ 7 E1* D2x*
18F 1 : 3 —f 2 : 2 2 : 0 : 1 : 1 þ þ 7 A1 D2x*
18M 2 : 2 2 : 2 2 : 2 2 : 0 : 2 : 0 þ 7 7 A1 A1*
18P 1 : 3 —f 2 : 2 2 : 0 : 1 : 1 þ þ 7 D2x* A1*
19F 2 : 2 2 : 2 2 : 2 2 : 0 : 2 : 0 þ 7 7 A1 A1*
19M 1 : 2 1 : 2 2 : 1 2 : 0 : 0 : 1 þ þ 7 B1 D2x*
19P 1 : 3 1 : 3 2 : 2 2 : 0 : 1 : 1 þ þ 7 A1* D2x*
19S 2 : 1 2 : 1 2 : 1 2 : 0 : 1 : 0 þ 7 7 A1* B1
28F 1 : 3 2 : 2 2 : 2 2 : 0 : 2 : 0 þ 7 7 A1 D1*
28M 2 : 3 2 : 3 2 : 3 2 : 0 : 3 : 0 þ 7 7 C1 A1*
28P 1 : 3 2 : 2 2 : 2 2 : 0 : 2 : 0 þ 7 7 D1* A1*
28S 1 : 4 2 : 3 2 : 3 2 : 0 : 3 : 0 þ 7 7 D1* C1
38F 1 : 3 2 : 2 2 : 2 2 : 0 : 2 : 0 þ 7 7 A1 D1*
38M 2 : 2 2 : 2 2 : 2 2 : 0 : 1 : 1 þ 7 7 A2 A1*
38P 1 : 3 2 : 2 2 : 2 2 : 0 : 2 : 0 þ 7 7 D1* A1*
aThe number indicates the family: F, father; M, mother; P, patient; S, healthy sib.
bThe fragments are shown in Figures 3 and 4.
cSee Table 2 for an explanation of the haplotype codes. *Carries steroid 21-hydroxylase deficiency.
dThe band ratios can be interpreted as father A1/A2* and mother: A2/D1*, but also as father A2/A1* and mother: A1/D2*.
eThe father was not available, but the paternal haplotypes could be deduced.
fThe resolution of the bands was not very good, but the 2.4 kb band was more intense.
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(16,26) using TaqI and BglII restriction analysis and CYP21A2
and C4 cDNA probes. The principal markers for CYP21A2 and
CYP21A1P are the 3.7 and 3.2 kb TaqI fragments, respectively
(Fig. 1). The 30 flanking region of these genes is usually
investigated by BglII digestion, because the CYP21A2 cDNA
probe overlaps the 2.4 and 2.5 kb TaqI fragments in this region
by only a few hundred base pairs, often resulting in poor
visualization of the bands. Normally, the estimated ratio of the
TaqI 2.4 and 2.5 kb bands is equal to the ratio of the BglII 12 and
11 kb bands. However, we could distinguish the 2.4 and 2.5 kb
bands on many autoradiograms (Table 1), and in some patients
with an apparent ‘large-scale conversion’ of CYP21A2 into
CYP21A1P, a discrepancy between the TaqI and BglII patterns
clearly existed. An example of a family study is shown in
Figure 2; the results were interpreted as follows: lane 1 (father):
two bimodular chromosomes with a total of two CYP21A2
genes, two CYP21A1P genes, two long telomeric C4 genes and
two long non-telomeric C4 genes; lane 2 (mother): one
bimodular and one monomodular chromosome with a total of
one CYP21A2 gene, two CYP21A1P genes, two long telomeric
C4 genes, and one short non-telomeric C4 gene; lane 3 (healthy
sister of the patient): one bimodular and one monomodular
chromosome with a total of two CYP21A2 genes, one
CYP21A1P gene, two long telomeric C4 genes and one long
non-telomeric C4 gene; lane 4 (patient with salt-losing steroid
21-hydroxylase deficiency): two bimodular chromosomes with
a total of one CYP21A2 gene, three CYP21A1P genes, two long
telomeric C4 genes, and one short and one long non-telomeric
C4 gene. The band ratios (listed in Table 1: family 19) were
determined by laser densitometry as reported earlier (16).
CYP21A2 mutation analysis (26) showed that the paternal defect
was the common splice junction mutation in the second intron
(Fig. 2A). The following haplotypes were deduced: a and b
(paternal): CYP21A2–C4long–CYP21A1P–C4long [haplotype
A1 in our earlier report (16)]; c (maternal): CYP21A2–C4long
(haplotype B1); d (maternal): CYP21A1P–C4short–
CYP21A1P–C4long (haplotype D2). Lane 5 in Figure 2 shows
an example of a person (not related to family 19) with two
monomodular chromosomes: one with a CYP21A2 gene and a
long C4 gene and one with a CYP21A1P gene and a long C4 gene.
Surprisingly, the band ratio of the TaqI 2.5 and 2.4 kb
fragments deviates from the band ratio of the BglII 11 and 12 kb
fragments in the mother and the patient in family 19 (Figure 2:
lanes 2 and 4). This finding, which suggests that the TNXB gene
on this chromosome is in part TNXA-like, triggered the
subsequent investigation of the structure of TNXB on similar
bimodular ‘conversion’ haplotypes. Table 1 shows the relative
band intensities and the deduced haplotypes for all eight
families where such a CYP21A1P–CYP21A1P haplotype was
found. Haplotype designations are the same as in our earlier
report (16). The families listed in Table 1 represent nine
CYP21A1P–CYP21A1P haplotypes. Even though the 2.4 and
2.5 kb TaqI fragments could not always be distinguished clearly,
four of these nine haplotypes apparently had two 2.4 kb TaqI
fragments and no 2.5 kb fragment; these chromosomes all had
one short and one long C4 gene. This suggested that the 120 bp
deletion was present not only in TNXA, as expected, but also in
TNXB. The other five chromosomes carried a 2.4 kb and a 2.5 kb
TaqI fragment, indicating that they did not have the 120 bp
deletion in TNXB; four of these had two long C4 genes, while in
one case (family 3), two interpretations were possible (Table 1).
We found such apparent discrepancies between the BglII and
TaqI restriction fragments on two other chromosomes. One of
these carried steroid 21-hydroxylase deficiency and resulted
from a de novo unequal crossover generating a monomodular
chromosome (P.F.J. Koppens, H.J.M. Smeets, I.J. de Wijs and
H.J. Degenhart, manuscript in preparation). The other was
found in a control on a bimodular chromosome where the TNXA
gene had partly assumed a TNXB-like structure that is probably
the same as reported earlier (36). All other chromosomes tested,
including 15 monomodular ‘CYP21A2 deletion’ alleles, had the
120 bp present in TNXB and, for multimodular chromosomes,
absent in TNXA. Table 2 lists the frequencies of the haplotypes
carrying steroid 21-hydroxylase in our study group.
Characteristics of normal TNXA and TNXB genes
The presence of a TNXA-like 120 bp deletion in the TNXB gene
adjacent to the centromeric CYP21A1P gene in four of the nine
Figure 2. Family study of TaqI and BglII restriction patterns and CYP21A2
defects. (A) Pedigree with CYP21A2 mutations at nucleotide 656 assigned to
each haplotype. (B) TaqI restriction patterns of genomic DNA hybridized to a
mixture of the CYP21A2 and C4 cDNA probes; fragment sizes are in kb; the C4
fragment sizes listed (7.0, 6.0, 5.4) are those traditionally used in the literature
(18), although the actual fragments are 0.15 kb larger. (C) BglII restriction
patterns obtained with the CYP21A2 probe only. Lanes 1–4: father, mother,
healthy sister, patient. Lane 5: unrelated individual with two monomodular
chromosomes, one with a CYP21A2 gene and one with a CYP21A1P
pseudogene; the C4 gene on each chromosome is ‘long’.
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‘large-scale conversion’ haplotypes in our population would
imply that these steroid 21-hydroxylase deficiency patients
would also be carriers of tenascin-X deficiency. To confirm this
finding and to further characterize the putative TNXB–TNXA
hybrid, a 2.8 kb region of either TNXA or TNXB was specifically
amplified. This region was selected because the forward primer
lies upstream of the duplication boundary and is specific to
TNXA or TNXB, while the reverse primer lies downstream of the
120 bp deletion (in this context, ‘downstream’ is relative to the
transcription of the TNXB gene). Thus, the amplified region
includes the TNXB–TNXA transition zone in the hybrid (Fig. 3).
To further narrow down the location of the TNXB–TNXA
breakpoint, we searched for informative differences between
normal TNXA and TNXB genes, other than the 120 bp deletion.
Comparison of published TNX sequences [EMBL/GenBank/
DDBJ accession nos S38953 (11), X71937 (13), AF077974
(36), AL049547 (37), AF019413 (38), U89337 (39),
AF086641 (14) and L26263 (9,40)] revealed several neutral
polymorphisms throughout the amplified region, some of
which can be detected by restriction analysis: PflMI at 276 bp
downstream of the duplication boundary of the RCCX module,
StyI at 719 bp, BstUI at 1626 bp, and PvuII at 2190 bp [Fig. 3;
sequence AL049547 (37) was used to compute fragment sizes
and nucleotide positions]. In contrast to the 120 bp deletion,
these differences do not cause a defect in the TNX gene, so
they cannot a priori be considered pseudogene (TNXA)-like,
and sequencing of the TNXA–TNXB hybrids would not locate a
typical transition point. To determine which of the polymorph-
isms could be used as specific markers, we amplified a large
number of TNXA and TNXB genes from individuals with one to
three copies of TNXA and two copies of TNXB, digested the
products with the restriction endonucleases mentioned above,
and analysed them on agarose or polyacrylamide gels.
The most informative restriction sites to distinguish TNXA
from TNXB were the PflMI site (present in 193 out of 241 TNXA
genes and 0 out of 294 TNXB genes) and the PvuII site (present
in 5 out of 131 TNXA genes and 85 out of 129 TNXB genes).
The StyI and BstUI sites were highly polymorphic in both genes,
and therefore could not be used as a reliable marker of either
TNXA or TNXB. All 298 TNXB genes tested contained the
120 bp deletion, as opposed to only 1 out of 270 TNXA genes.
Characteristics of TNXB–TNXA hybrid genes
Since the amplified region contains only a single PflMI site,
detection of this polymorphism and of the 120 bp difference
could conveniently be done in a single experiment. Figure 3
shows the fragments that can be expected after PflMI restriction
of the TNXA and TNXB PCR products; the restriction fragments
found in each family with a ‘large-scale conversion’ haplotype
are listed in Table 1.
Typical PflMI banding patterns are shown in Figure 4. Out of the
four bimodular CYP21A1P–CYP21A1P chromosomes with the
120 bp deletion in TNXB, one carried the PflMI site at bp 276
(Fig. 4: lane 6); the remaining three, and the five CYP21A1P–
CYP21A1P chromosomes without the 120 bp deletion in TNXB,
did not have this site (Fig. 4: lane 5). This shows that in one case,
the transition between a TNXA-like sequence and a TNXB-like
sequence lies within 276 bp of the RCCX duplication boundary. In
the other three cases, the transition probably lies further down-
stream, because absence of the PflMI site is a TNXB-like feature
(although it also occurs in 20% of the TNXA genes). All four
genes are, of course, TNXA-like at the site of the 120 bp insertion
(bp 2290) and possibly already at bp 2190, since they did not carry
a PvuII site found in most TNXB genes (results not shown).
DISCUSSION
TNXB–TNXA hybrids
Combined defectiveness of the CYP21A2 and TNXB genes has
so far been described in a few isolated cases in CYP21A2
deletions caused by meiotic unequal crossover. We here report
Table 2. CYP21/C4/TNX haplotypes carrying classical steroid 21-hydroxylase deficiency in Dutch patients
Modularity Genesa Codeb Number
Monomodular C4L; 21A2; XB B1 6
C4S; 21A2; XB B2 3
C4L; 21A1P–A2; XB E1 15
C4L; 21A1P; XA–XB E1x 1
Bimodular C4L þ C4L; 21A1P þ 21A2; XA þ XB A1 26 or 27c
C4L þ C4S; 21A1P þ 21A2; XA þ XB A2 11 or 10c
C4L þ C4L; 21A1P þ 21A1P–A2; XA þ XB D1 5 or 4c
C4L þ C4S; 21A1P þ 21A1P–A2; XA þ XB D2 0 or 1c
C4L þ C4S; 21A1P þ 21A1P; XA þ XA–XB D2x 4
Trimodular C4L þ C4L þ C4L; 21A1P þ 21A1P þ 21A2; XA þ XA þ XB C1 1
C4L þ C4S þ C4S; 21A1P þ 21A1P þ 21A2; XA þ XA þ XB C2 1
C4L þ C4L þ C4S; 21A1P þ 21A1P þ 21A2; XA þ XA þ XB C3 1
C4L þ C4S þ C4S; 21A1P þ 21A2 þ 21A2; XA þ XA þ XB F1 0
C4S þ C4S þ C4S; 21A1P þ 21A2 þ 21A2; XA þ XA þ XB F2 1
Total 77
aC4L, C4S, long, short; 21A1P–A2, CYP21 hybrid; XA–XB, TNX hybrid.
bThe haplotype codes are the same as in our earlier report (16); the appended ‘x’ indicates the haplotypes with a TNXB–TNXB hybrid rather than a CYP21A1P–
CYP21A2 hybrid; ‘D2x’ is the novel dual deficiency haplotype described in this report.
cExact numbers are not certain, because the results for family 3 could be interpreted in different ways (Table 1).
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that such ‘double–deficiency’ alleles are indeed rare on
monomodular chromosomes, but relatively common (four out
of nine cases) on bimodular chromosomes with two
CYP21A1P-like genes (usually termed ‘large-scale conver-
sions’ in the literature). This haplotype is characterized by two
2.4 kb TaqI fragments matching the 120 bp deletion in both
TNX genes, and distinguishing it from previously described
‘large-scale conversions’ which have one 2.4 and one 2.5 kb
fragment. Given the large number of CYP21A2/C4 haplotyping
reports available to date [most of which were recently reviewed
by White and Speiser (5)], it is surprising that this haplotype
has not been documented before: an apparently similar case
was reported only once (41), before the discovery of the TNX
genes. Poor resolution or poor visualization of the 2.4 and
2.5 kb bands sometimes (but not always) hampers the analysis
when a CYP21A2 cDNA probe is used. However, studies with
probes that overlap a large part of these fragments (15,21,42)
did not detect this haplotype either. To find the TNXB–TNXA
transition zone in this type of hybrid, we checked which of the
polymorphisms in published TNX sequences (for references,
see the Results section) are reliable markers of ‘TNXA-ness’ or
‘TNXB-ness’. A characteristic PflMI site at 276 bp downstream
of the RCCX duplication boundary was present in one of the
four TNXB–TNXA hybrids, but absent in the others, indicating
that at least two distinct transition zones exist: upstream of the
PflMI site in one case (family 14) and downstream in the others
(Table 1 and Fig. 5). Previously, we characterized the CYP21P
pseudogenes in these, and other, haplotypes. The haplotype
with the PflMI site (in family 14; Table 1) also carried different
CYP21P genes than the other three haplotypes [see Table 5 in
our earlier report (26): second haplotype of family 14]. This
suggests that these hybrids (Fig. 5C,D) were created by
independently occurring recombinations instead of a by a
single event followed by secondary mutation that caused the
PflMI difference. In our patient group (26), TNXB–TNXA
hybrids were found on 4 out of 77 chromosomes, a frequency
of 0.052 (95% confidence interval 0.018–0.12) (43).
Considering a carrier rate for classical steroid 21-hydroxylase
deficiency of 1 : 50, we estimate the frequency of such dual-
deficiency alleles in the general population in The Netherlands
at 1 : 1000. Since two independent variants exist in the
relatively small patient group examined here, it seems likely
that a systematic re-evaluation of apparent large-scale con-
versions in other populations by a suitable PCR method
(33; this report) will detect similar haplotypes. Interestingly,
TNXB–TNXA hybrid genes were recently reported in two
Dutch patients suffering from Ehlers–Danlos syndrome (34).
The number of RCCX modules was not determined in that
Figure 3. Amplified region of the TNXB and TNXA genes. Open boxes are exons; the triangle indicates the site of the 120 bp deletion. The bold arrows represent
the primer sites for the TNX PCRs; the reverse primer is the same for both genes, but the forward primers are specific and their starting positions differ by 36 bp.
Polymorphic restriction sites deduced from published TNXA and TNXB sequences are shown. The centre of the figure indicates the extent of the PflMI restriction
fragments (2344, 2688, 2808) shown in Figure 4.
Figure 4. PflMI restriction analysis of PCR-amplified fragments of the TNXA
and TNXB genes. Lane 1: TNXA without the PflMI site. Lane 2: TNXA, hetero-
zygous for the PflMI site. Lane 3: TNXA, homozygous for the PflMI site.
Lane 4: TNXB, no PflMI site. Lane 5: TNXB, heterozygous for the 120 bp dele-
tion without the PflMI site. Lane 6: TNXB, heterozygous for the 120 bp deletion
with the PflMI site. Left: 5ml SmartLadder (Eurogentec, Seraing, Belgium);
electrophoresis was for 28 h at 40 V on 1% agarose.
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study, so it seems possible that these patients have the
bimodular structure described here.
Recombinational mechanisms
Chromosomes carrying two RCCX modules, each with a
CYP21A1P-like gene, have been called ‘large-scale gene
conversions’ because, as compared with the typical layout,
the CYP21A2 gene appears to have been converted into a
CYP21A1P gene. It has, however, become clear that the
‘converted’ CYP21A1P gene on such chromosomes is either a
CYP21A1P–CYP21A2 hybrid (25,26) or a regular CYP21A1P
gene adjacent to a TNXA–TNXB hybrid (this report), and thus
structurally indistinguishable from the CYP21A1P genes on
‘CYP21A2-deletion’ chromosomes. Crossing-over between
misaligned monomodular and bimodular chromosomes during
meiosis was proposed more than a decade ago as a mechanism
causing CYP21A2 deletions (1,7,15,20,28). Two more recent
reports (14,36) have described this mechanism in considerable
detail for CYP21A2 deletions where the putative recombination
occurred within the TNX genes. The recombination breakpoint
in the TNXB–TNXA hybrid (on a monomodular chromosome)
described there (14) was localized between the 120 bp deletion
and the centromeric duplication boundary of the RCCX
module, and this hybrid is therefore quite similar to those
described here on bimodular chromosomes. Although definite
proof awaits the description of a de novo event, the structural
similarity makes it highly likely that bimodular CYP21A1P–
CYP21A1P haplotypes arise by the same mechanism as
monomodular CYP21A1P-only haplotypes, namely meiotic
unequal crossover: in this case involving a trimodular
CYP21A1P–CYP21A1P–CYP21A2 chromosome (1,15). Such
a recombination between a bimodular and a monomodular
chromosome (1) would only differ from those described else-
where (14,20,36) by the presence of one additional RCCX
module on each chromosome. An outline of these putative
recombination events is shown in Figure 6. We therefore
propose that, in this context, the term ‘gene conversion’
be reserved for small-scale events only, ideally with demon-
strable non-converted regions on either side of the converted
region. Gene conversion is indeed a reasonable explanation for
small-scale CYP21A2–CYP21A1P sequence transfer, as
supported by studies of de novo mutations (44–46) and sperm
cells (47). Although historically understandable, the term
‘large-scale gene conversion’ in its present sense suggests a
mechanism that probably never occurs between RCCX
modules. Instead, the term ‘CYP21A2 deletion by unequal
crossover’ adequately describes all chromosomes with a hybrid
RCCX module and without a CYP21A2 gene, irrespective of
the number of CYP21A1P genes.
MATERIALS AND METHODS
Subjects and haplotyping
The study population of 21-hydroxylase deficiency patients,
family members and controls was the same as before (26); a
family where a de novo CYP21 deletion occurred was now
included into the haplotype count in Table 2. CYP21/C4
haplotyping was done as described earlier (2,16). Briefly, TaqI
and BglII restriction patterns were obtained with the CYP21A2
cDNA probe pC21/3c (6) and the 50 section of the C4 cDNA probe
pAT-A (48). Band ratios were measured by laser densitometry, and
haplotypes were deduced from the segregation of the patterns (16).
Amplification and restriction analysis of
TNXA and TNXB
Parts of TNXA and TNXB that encompass the site of the 120 bp
deletion normally found in TNXA only were specifically
amplified. The forward primer for TNXB (TCTCTGCCCT-
GGGAATGACAG) lies beyond the duplication boundary
of the RCCX module, in the large non-duplicated part
Figure 5. Amplified region of TNXA and TNXB (bottom) showing the site of the 120 bp deletion (triangle) in TNXA and the beginning of the TaqI fragment that partly
overlaps the CYP21A2 or CYP21A1P gene (Fig. 1). The location of the TaqI site in the TNX genes is the same relative to the nearby RCCX duplication boundary, but
the 120 bp size difference determines whether the fragment is 2.4 or 2.5 kb. The polymorphic sites used as markers for TNXA or TNXB are shown. The four amplified
stretches of DNA are (A) regular TNXA PCR; (B) regular TNXB PCR, which produces similar stretches for a haplotype with a normal CYP21A2 gene and one with a
CYP21A2–CYP21A1P hybrid; (C) and (D) TNXB PCR of a TNXB–TNXA hybrid with two different conversion zones, typical of the novel haplotype described here.
TNXA-like sequences are shown in black and TNXB-like sequences in white, and putative transition zones between them are hatched. Top: scale in bp.
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of the TNXB gene. The forward primer for TNXA
(CTTGAGCTGCAGATGGGATAC) lies within the RP2 pseu-
dogene. The reverse primer (CAATCCCCACCCTGAA-
CAAGT) was the same for both genes, and lies between the
site of the 120 bp deletion and the 30 end of the CYP21A2/
CYP21A1P gene (Fig. 3). A touchdown PCR protocol was used
to amplify these stretches of 2.8 kb: first, 8 cycles of 30 s at
94C, 60 s at 66C decreasing by 0.5C/cycle, and 3 min at 72C;
next, 26 cycles of 30 s at 94C, 60 s at 62C, and 3 min at 72C
extending by 30 s per cycle. Amplification was done with
0.5 units of Thermoperfect DNA polymerase (Integro,
Leuvenheim, The Netherlands) in the presence of 1.5 mM
MgCl2 and 1% formamide. The size of the PCR product directly
shows the presence or absence of the 120 bp deletion/insertion.
For further analysis, the PCR products were digested with PflMI
(New England Biolabs, Beverly, MA, USA), StyI (Eurogentec,
Seraing, Belgium), BstUI (New England Biolabs, Beverly, MA,
USA) or PvuII (Gibco BRL, Gaithersburg, MD, USA). The
products were analysed on agarose or polyacrylamide gels.
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